
    
      There is a screening period of up to 6 weeks, a treatment period of a minimum of 52 weeks and
      a maximum of approximately up to 3 years after last patient is randomized, and a
      post-treatment follow-up period of 4 weeks. A total of up to 900 patients will be randomized
      in a 1:1 ratio to receive either open-label FG-4592 or Active Control (Epoetin alfa).
    
  